Accelerating Toward the Clinic in 2025
Trogenix has successfully achieved all milestones in platform and asset development, positioning the company to enter the clinic in 2025 with its lead programme.
Transformative Potential
Lead Programme: Glioblastoma (GBM) – TGX-007
Curative preclinical results
Manufacturing milestone achieved
Ready to enter the clinic in 2025
Pipeline Expansion: Colorectal Liver Metastasis (CRLM) and Hepatocellular Carcinoma (HCC)
Trogenix has accelerated preclinical validation for CRLM and HCC in collaboration with both the Cancer Research UK Scotland Institute and Prof. Owen Sansom and Prof. Tom Bird, global leaders in these cancers.
H1 2025: Efficacy data in advanced syngeneic models
H2 2025: IND-enabling safety, toxicity, and biodistribution studies.
Broader Applications of the Odysseus™ Platform
The versatility of the Odysseus™ Platform has been advanced in additional solid tumour indications, including non-small cell lung cancer, as well as in regenerative medicine applications targeting fibrosis.
Strengthened Leadership for 2025 Growth
The dynamic and experienced founding team
Dr. Ken Macnamara, Prof. Steve Pollard, and Dr. Dima Kuzmin – has been further strengthened with the addition of industry leaders:
Dr. Juanma Iglesias, Chief Technology Officer (CTO): Brings decades of experience in ATMP and oncology product development.
Dr Ben Southgate, Head of Bioinformatics and Machine Learning: Spearheads development of the Odysseus™ Platform.
Bryn Dixon, VP of Clinical Development: Offers extensive experience in executing Phase 1–3 oncology trials.
Tay Salimullah, Board Member, Chief Strategy Officer: Joins from Novartis Gene Therapy, bringing unique expertise in global roll out of ATMPs.
Supported by a prestigious Scientific Advisory Board of world leading experts in gene regulation, synthetic biology, immunotherapy, oncology, gene therapy, regenerative medicine and neurosurgery.
Out of Stealth
Incubated by 4BIO Capital in 2023, Trogenix has through 2024 brought in additional venture backing with IQ Capital, Cancer Research Horizons, AIN Ventures, Old College Capital, and the U.S. National Brain Tumor Society (their first overseas investment).
